<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">KIM, YEON JOO</style></author><author><style face="normal" font="default" size="100%">SONG, SI YEOL</style></author><author><style face="normal" font="default" size="100%">KIM, WANLIM</style></author><author><style face="normal" font="default" size="100%">LEE, JONGSEOK</style></author><author><style face="normal" font="default" size="100%">AHN, JIN-HEE</style></author><author><style face="normal" font="default" size="100%">KIM, JEONG EUN</style></author><author><style face="normal" font="default" size="100%">CHUNG, HYE WON</style></author><author><style face="normal" font="default" size="100%">JEONG, SEONG-YUN</style></author><author><style face="normal" font="default" size="100%">CHOI, EUN KYUNG</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Undervaluation of Radiotherapy for Gross Desmoid Tumors: The Need for Absolute Volume Assessment</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1777-1784</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.12437</style></doi><volume><style face="normal" font="default" size="100%">35</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: To compare absolute volume (AV) assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) for the response evaluation of desmoid tumors (DTs) treated with radiotherapy. Patients and Methods: Eighteen patients with DTs ≥3 cm in size were included. Results: The median follow-up duration was 78.0 months. Five patients achieved a complete response according to RECIST, seven reached a partial response (PR), and one eventually exhibited progression. The overall response rate was 61%, the median time to PR was 8.0 months. Six patients achieved stable disease, although three developed progressions. Of the six patients with a PR, the median change in maximum diameter was −46%, and the median change in maximum volume was −84%. Three patients could have been diagnosed with progression at least 6 months earlier if the AV increment was considered. Conclusion: An AV assessment is essential for an accurate response assessment of DTs and radiotherapy seems feasible as a first-line treatment for DTs.</style></abstract></record></records></xml>